DV
Dividend Vision

EPRX — Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

Total return is 127.8% over the past 2.4 years, 74.0 points ahead of SPY at 53.8%. Its deepest 1-year drawdown was 35.9%.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing drug delivery products for therapeutic areas with unmet medical needs, utilizing its proprietary Diffusphere technology platform. Its pipeline includes EP-104IAR in Phase III trials for knee osteoarthritis and EP-104GI in Phase II trials for eosinophilic esophagitis. The company does not currently distribute dividends and is primarily oriented toward investors seeking exposure to early-stage biotech development rather than income generation.

EPRX key facts

Asset type
Stock
Asset class
Equity
Inception date
04/05/2024
Last close
$6.72
Market cap
$430,504,608
Average volume
164700.0
Beta
1.498
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.05